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Abstract 
Background: Because of the shared mean of transmission, hepatitis B virus (HBV) is one of an important cause of 
co-morbidity and mortality in peoples living with HIV/AIDS. Hence, the aim of this study was to determine the sero-
prevalence of HBV infection and associated risk factors in HIV/AIDS positive individuals attending ART clinic at Mekelle 
hospital, Mekelle, Northern Ethiopia.
Methods: A cross sectional study was conducted from August to October 2014 in HIV/AIDS positive adult indi-
viduals. Socio-demographic data and other explanatory variables were collected from 508 study participants using 
pre-tested and structured questionnaire-based interviews. Serum hepatitis B surface antigen (HBsAg) was detected 
using commercially available rapid test and third generation enzyme-linked immunosorbent assay (ELISA). Bivariate 
and multivariate analysis, using SPSS V.20.0, were performed to assess the variables associated with HBV infection and 
P value less than 0.05 was considered as statistically significant.
Results: A total of 508 study participants, 305 females and 203 males were included in this study with the mean 
(+SD) age of 37.8 + 9.6. The sero-prevalence of HBsAg was 5.9 %. Male gender (AOR = 2.6, 95 % CI 1.2–5.7), multiple 
sexual partners (AOR = 4.2, 95 % CI 1.3–13.1) and CD4 count <200 cells/μl (AOR = 3.5, 95 % CI 1.1–11.2) were signifi-
cantly associated with HBsAg positivity.
Conclusion: The prevalence of HBsAg was similar to the general population. However, HIV/AIDS positive individu-
als with reduced CD4 count, <200 cells/μl, showed a significant association with HBsAg seropositivity. Therefore, we 
recommended, all HIV/AIDS positive individuals should be screened for HBsAg during their follow for better treatment 
outcome and minimize risks of HBV transmission.
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Background
Human immunodeficiency virus (HIV) related mortal-
ity has been drastically reduced with expanded and wide 
use of anti-retroviral therapy (ART) [1, 2]. However, this 
improved survival of HIV/AIDS positive individuals 
created an enabling condition for the hepatitis B Virus 
(HBV) to establish chronic infection and become a major 
cause of co-morbidity in HIV/AIDS infected individuals 
[3]. More interestingly, the course of acute HBV infection 
may be modified in the presence of HIV/AIDS infection, 
with a lower incidence of icteric illness and lower rates 
of spontaneous clearance of HBV [4]. Therefore, the cur-
rent HIV/AIDS treatment guidelines recommend the use 
of combination therapy, including two HBV active nucle-
oside analogues, for any HIV/AIDS-HBV co-infected 
patients initiating antiretroviral therapy (ART) [5].
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Approximately two billion people have been infected 
with HBV and of those 400 million people developed 
chronic HBV infection worldwide [6]. In addition, 
despite the availability of effective vaccine, about one 
million people die annually by HBV-related disease. 
Approximately 4 million HIV/AIDS positive individu-
als are co-infected with HBV worldwide [7]. The pro-
portion and risk factors of HBV-HIV co-infection varies 
widely with geographical distribution [2]. The study sug-
gested that HBV-HIV/AIDS co-infected individuals were 
at increased risk of AIDS or death as compared to HIV/
AIDS infected only [2, 8]. In resource limiting countries, 
the main route of transmission of HBV infection is verti-
cal and/or perinatal transmission, and hence, individuals 
are acquired at the early age of life. Contact with infected 
blood or body fluids (including semen and saliva) are also 
common routes of transmission in developed nations 
[10]. However, blood and blood products are the major 
reservoirs for HBV infection which also shared transmis-
sion routes with HIV/AIDS [11, 12].
HIV/AIDS-HBV co-infection is common particularly 
in areas of endemic HBV infection [13]. Ethiopia is one 
of the endemic Sub-Saharan African countries for HBV. 
However, studies were limited to only high-risk groups, 
HIV/AIDS positive individuals. In Ethiopia, majorities of 
the previous studies were conducted in pregnant women 
[14] and healthy blood donors [15]. Moreover, HIV/AIDS 
infected individuals were treated with ART without prior 
screening for HBV infection. As a consequence, ART 
drug resistant and severe liver toxicity and cirrhosis are 
very high [16]. Hence, the aim of this study was to deter-
mine the sero-prevalence of HBV and associated risk fac-
tors among HIV-positive adult individuals attending ART 
clinic at Mekelle hospital, Tigray, Northern Ethiopia.
Methods
Study design and period
A cross sectional hospital based study was conducted 
among HIV/AIDS positive adults who visited the study 
site from August to October 2014.
Study area, sample size determination and sampling 
method
The study was conducted at Mekelle hospital ART clinic, 
Mekelle, Ethiopia. The hospital is serving for about 
800,500 people and giving treatment and follow-up for 
4035 HIV/AIDS seropositive people. The study partici-
pants were HIV/AIDS seropositive adults who visited the 
ART clinic during the study period. The sample size was 
calculated using single population proportion formula by 
assuming the prevalence of HBV 6 % [15], 95 % CI and 
2 % marginal error. Since the source of the study popu-
lation was less than 10,000, finite population correction 
formula was also used to adjust the necessary sample 
size. Accordingly, a total of 525 study participants were 
enrolled including the 10 % non-response rate. The study 
participants were expected to represent rest of HIV/
AIDS positive population in the study area because they 
have same socio-demographic and health service provi-
sion related matters.
Data collection
Socio-demographic data and other explanatory variables 
were collected using validated and pretested question-
naire by trained nurses working at the ART clinic. Three 
milliliters of whole blood was also collected from each 
participant by venous puncture, and serum was sepa-
rated. The serum was used for rapid serological HBsAg 
test and enzyme-linked immunosorbent assay (ELISA).
Laboratory detection of hepatitis B virus
In-vitro serological test was performed to detect HBsAg 
using one step rapid immunochromatographic test 
(Tulip’s Instant (Tulip Diagnostics(P) Ltd. 88/89, Phase 
II C, Verna Ind. Est., Verna, Goa-403 722, India). The 
test results were interpreted and reported as positive or 
negative based on the manufacture’s instruction. HBsAg 
positive serum samples were further confirmed using 
3rd generation ELISA assay at Tigray Regional Red Cross 
Laboratory.
Quality control
The standard operational procedures (SOP) of pre-ana-
lytical to post analytical quality control techniques of 
the laboratory were strictly followed. The quality con-
trol for HBsAg test kits was monitored by using positive 
and negative control samples before testing the patients’ 
serum, and in every opening of new kits. Similarly, ELISA 
test results were also assured using positive and negative 
controls according to the manufacturer’s manual. The 
data quality was also maintained by training the data col-
lectors before the actual data collection begin. Moreover, 
daily checking and monitoring of results were done by 
the principal investigators.
Statistical analysis
Data were cleaned and entered to SPSS v. 20.0. The asso-
ciation between each predictor and outcome variables 
was determined by using binary logistic regression analy-
sis. All predictor variables with the P value less than 0.2 
in the bivariate analysis were entered to the multivariate 
model to check if the variables were associated indepen-
dently [12]. Odds ratio at 95 % CI and P < 0.05 were used 
to measure the strength of the association.
The final model was built by using Enter method stand-
ard regression model building technique. Before building 
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the final model, the multi-co-linearity effect was assessed 
using linear regression and the mean VIF  >5 was used 
as cut-off point [16]. The final model was then tested 
for its goodness of fit by Hosmer and Lemeshow and P 
value > 0.05 was best fit [17]. The final multivariate model 
included variables that had significant association at 
P < 0.05.
Ethical consideration
This research project was approved and ethically cleared 
by Ethical Review committee of College of Health Sci-
ence, Mekelle University and letter of cooperation 
was written to the institutional review board of Tigray 
Regional Health Bureau for approval. Consent was also 
obtained from each study participant. HBsAg positive 
test results were communicated to the ART clinic for 
appropriate action and follow up. Moreover, since TDF-
3TC-EFV was more effective than AZT-3TC-EFV ART 
combination therapy, we recommended to the regional 
health bureau to shift to TDF-3CT-EFV combination 
therapy. Our result was also presented to physicians 
working at the ART clinic.
Results
Socio‑demographic characteristics
A total of 525 study participants were enrolled and 
of this 17 were excluded due to incomplete data. The 
mean(+SD) age of the study participants was 37.8 + 9.6 
and most, 485 (95.5 %) were urban resident. Three hun-
dred seventy one (73 %) of the participants were attended 
at least primary school. Seventy three (14.4  %) and 106 
(20.9 %) were civil servants and housewives respectively 
(Table 1).
HBV sero‑prevalence
In this study, using the rapid immunochromatographic 
test, 30 (5.9 %) were positive for HBsAg and then all posi-
tive serum samples by rapid test were retested with more 
specific test, ELISA. Of the total HBsAg positive individ-
uals 19 (9.4 %) were males. Regarding the marital status, 
18 (6.7 %) of the HBsAg positive participants were mar-
ried. Twelve (7.1 %) and 7 (6.6 %) of the participants posi-
tive for HBsAg were attended elementary school and civil 
servants respectively.
Associated risk factors & clinical characteristics
In the bivariate analysis sex, multiple sexual partners, sur-
gical history, unsafe injection, and CD4 count <200 cells/μl 
has shown statistically significant association with HBsAg 
seropositivity (Table  2). The significantly associated vari-
ables were entered into multivariate model and: male 
(AOR  =  2.6, 95  % CI 1.2–5.7), multiple sexual partners 
(AOR = 4.2, 95 % CI 1.3–13.1) and CD4 count <200 cells/
Table 1 Bivariate analysis of  socio-demographic charac-
ters of HBV infection among HIV positive individuals
COR crude odds ratio
* Statistically significant at P < 0.2




Yes = 30 No = 478 COR (95 % 
CI)
P value
Total n (%) +ve N (%) −ve N (%)
Sex
 Female 305 (60) 11 (3.6) 294 (96.4) 1




 18–24 29 (5.7) 1 (3.4) 28 (96.6) 1
 25–34 152 (29.9) 7 (4.6) 145 (95.4) 1.4 
(0.2–11.4)
0.782
 35–44 198 (39) 18 (9.1) 180(90.9) 2.8 
(0.4–21.8)
0.326




 Rural 23 (4.5) 2 (8.7) 21 (91.3) 1.6 (0.34–
7.0)
0.564
 Urban 485 (95.5) 28 (5.8) 457 (94.2) 1
Marital status
 Single 70 (13.8) 4 (5.6) 67 (94.4) 1.8 
(0.3–10.0)
0.522
 Married 267 (52.6) 19 (7.1) 248 (92.8) 2.3 
(0.5–10.0)
0.282
 Divorced 109 (21.5) 5 (4.6) 104 (95.4) 1.4 
(0.3–7.5)
0.682
 Widowed 62 (12) 3 (4.9) 58 (95.1) 1
Education





169 (33.3) 12 (7.1) 157 (92.9) 1.5 
(0.5–5.0)
0.462






85 (16.7) 4 (4.7) 81 (95.3) 1
Occupation
 Farmer 35 (6.9) 2 (5.7) 33 (94.3) 1





73 (14.4) 7 (9.6) 66 (90.4) 1.8 
(0.3–8.9)
0.500





106 (20.9) 2 (1.9) 104 (98.1) 0.3 
(0.0–2.3)
0.260
 No work 68 (13.4) 5 (7.40) 63 (92.6) 1.3 
(0.2–7.1)
0.755
 Othera 125 (24.6) 7 (5.6) 118 (94.4) 1.0 
(0.2–5.0)
0.979
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μl (AOR = 3.5, 95 % CI 1.1–11.2) were found significantly 
associated with HBsAg positivity (Table  3). Taking AZT-
3TC-EFV (AOR = 2.0, 95 % CI 0.7–6.0) were showed an 
increased HBsAg positivity than those who were taking 
TDF-3TC-EFV based combined ART therapy, though the 
difference was not statistically significant (Table 2).
Discussion
In this study, the sero-prevalence of HBV was 5.9 % and 
this finding was similar with studies reported in Tigray 
and Amhara regions, Ethiopia (6.2  %) [18] and (5.7  %) 
[14] respectively. Furthermore, our finding was also 
similar with a study conducted in South Africa [19]. This 
Table 2 Bivariate analysis of associated risk factors for HBV infection in Mekelle among HIV positive individuals
COR crude odds ratio
* Statistically significant at P < 0.2
Variables HBV sero status
Total = 508 Yes = 30 No = 478 COR (95 % CI) P value
Total n (%) +ve N (%) −ve N (%)
Blood transfusion
 No 467 (91.9) 27 (5.8) 440 (94.2) 1
 Yes 41 (8.1) 3 (7.3) 38 (92.7) 1.3 (0.4–4.4) 0.690
Unsafe injection
 No 475 (83.5) 26 (5.5) 449 (94.5) 1
 Yes 33 (6.5) 4 (12.1) 29 (87.9) 2.4 (0.8–7.3) 0.128*
Multiple sexual partners
 No 482 (94.9) 25 (5.2) 457 (94.8) 1
 Yes 26 (5.1) 5 (19.2) 21 (80.8) 4.4 (1.5–12.5) 0.006*
Surgical history
 No 408 (80.3) 20 (4.9) 388 (95.1) 1
 Yes 100 (19.7) 10 (10) 90 (90) 2.2 (1.0–4.8) 0.058*
Tooth extraction
 No 319 (62.8) 20 (6.3) 299 (93.7) 1
 Yes 189 (37.2) 10 (5.3) 179 (94.7) 0.8 (0.4–1.8) 0.651
Abortion
 No 475 (93.5) 29 (6.1) 446 (93.9) 1
 Yes 33 (6.5) 1 (3) 32 (97.0) 0.5 (0.1–3.6) 0.478
Tattooing
 No 447 (88) 27 (6) 420 (94) 1
 Yes 61 (12) 3 (4.9) 58 (95.1) 0.8 (0.2–2.7) 0.728
Family having liver disease
 No 468 (92) 28 (6) 440 (94) 1
 Yes 40 (7.9) 2 (5) 38 (95) 0.8 (0.2–3.6) 0.800
CD4 count
 <200 cells/μl 85 (16.5) 9 (10.6) 76 (89.4.) 3.9 (1.3–12.1) 0.018*
 200–350 cells/μl 118 (23.2) 7 (5.9) 111 (94.1) 2.1 (0.6–6.7) 0.221
 351–499 cells/μl 135 (26.6) 9 (6.7) 126 (93.3) 2.4 (0.8–7.2) 0.133*
 ≧500 cells/μl 170 (33.5) 5 (2.9) 165 (97.1) 1
ART status
 Pre ART 65 (12.8) 2 (3.1) 63 (96.9) 1
 ART 443 (87.2) 28 (6.3) 415 (93.7) 2.1 (0.5–9.1) 0.311
ART drugs
 AZT,3T, Nuv 106 (24.5)  7 (6.6) 99 (93.4) 1.2 (0.5–3.4) 0.678
 AZT,3T, Evf 58 (13.4) 6 (10.3) 52 (89.7) 2.0 (0.7–6.0) 0.200
 TDF,3T, Nuv 101 (23.4) 6 (5.9) 95 (94.1) 1.1 (0.4–3.2) 0.849
 TDF,3T, EFV 167 (38.7) 9 (5.4) 158 (94.6) 1
Page 5 of 7Weldemhret et al. AIDS Res Ther  (2016) 13:6 
might be due the similarity in HBV endemicity and clini-
cal characteristic of study participants [2]. In the inter-
mediate endemicity (2–7  %) areas, perinatal and sexual 
contact is the predominant routes of transmission for 
HBV infection [9]. On the other hand, it was relatively 
higher as compared with studies conducted in the United 
States of America (3 %) [8]. This might be due to the dif-
ference in clinical characteristics of study participants 
because half of the study participants in the USA study 
were Pre-ART (not started ART), in other words, their 
CD4 count were at least >200 cells/µl. However, 87 % of 
our participants were under ART (CD4 count <200 cells/
µl) treatment [20], which an enabling condition for HBV 
to establish persistent infection. Other possible reasons 
could be the level of knowledge of HBV and HIV trans-
mission between the communities. Other possible jus-
tification could the health services provision difference: 
though did not assess for vertical transmission, it could 
be one of the reasons for the higher prevalence in our 
study. On the contrary, studies conducted in Nigeria 
(15.4  %) [21] and China (19.4  %) [22] were significantly 
higher HBV prevalence and this may be due to the diag-
nostic tools they used, the HBV DNA RT-PCR versus 
HBsAg ELISA assay.
This study revealed that males were 2.59 times more 
likely to expose with HBV than females. Similarly, his-
tory of having multiple sexual partners was significantly 
more frequent among males (6.9 %) than females (3.9 %) 
(Table 3).The possible explanation could be, in developing 
countries, especially in the rural and semi-urban commu-
nities, because of their job nature, males travel more fre-
quently than females. This was comparable with studies 
conducted in Gondar teaching hospital, Ethiopia, Pasteur 
institute, Morocco and Pakistani Punjab [14, 22–25].
Though the difference was not statistically significant, 
the mean CD4 cell count (Mean  +  SD) for HBV-HIV/
AIDS co-infection (320  +  126  cells/μl) was lower than 
HIV/AIDS alone (402 + 201 cells/μl). The reason for is; 
at very lower CD4 count (200 cells/µl), the course of HBV 
infection may be different from the immune-competent 
individuals, meaning the primary infection will be a mild 
liver disease with a lower incidence of icteric and lower 
rates of spontaneous clearance of HBV. However, this is 
enabling condition for HBV to establish chronic infection 
[4, 23–26]. This finding was consistent with studies con-
ducted in Gondar, Ethiopia [14] and Nigeria [27].
Furthermore, significantly higher HBsAg sero-
positivity was observed among individuals with CD4 
count <200 cells/ul (AOR = 3.543, 95 % CI 1.119–11.214) 
than individuals with CD4 count ≥500 cells/μl (Table 3). 
In this study, we compared the HBsAg seroconversion 
rate between study participants who were taking AZT-
3TC-EFV and TDF-3TC-EFV combined ART therapy 
and statistically insignificant higher (Adjusted P  =  0.2) 
HBsAg seropositivity was observed in AZT-3TC-EFV 
treatment follow up attendants. This can be explained 
by efficacy difference between the two treatment regi-
men; where TDF-3TC-EFV, a nucleotide analogue which 
inhibited the polymerase and viral replication, has more 
efficient than lamivudine (3TC) and Zidovudine(AZT) in 
the treatment of both HIV/AIDS and HBV [28].This was 
similar with a study conducted in Kenya [29]. Similarly, 
other studies also reported that TDF-3TC-EFV com-
bined ART therapy significantly reduced the level of HBV 
DNA level in the patient’s serum [28, 30]. another inter-
esting result from the African Temprano Trial, presented 
at the conference on Retroviruses and Opportunistic 
Infection (CROI 2015), showed that starting HIV/AIDS 
treatment (TDF was one of the drugs they used) at a CD4 
cell count above 500 reduced the risk of serious illness 
and death by 44 % when compared to starting treatment 
according to WHO guidelines [31].
Socio-demographic characteristics like age, residence, 
marital status, education and occupation were not sig-
nificantly associated to HBsAg positivity. Likewise, of 
the risk factors history of blood transfusion, unsafe injec-
tion, tooth extraction, history of surgery, catheterization, 
abortion, tattooing and having a history of family liver 
disease did not show statistically significant association 
with HBV infection and this was consistent with studies 
done in Goba, Ethiopia [32].
Conclusion
HBsAg seropositivity among individuals with CD4 
count  <200  cells/µl is significantly higher than with 
CD4 count  >200  cells/µl. HBsAg seropositivity was also 
higher among the AZT-3TC-EFV than TDF-3TC-EFV 
Table 3 Multivariate analysis of  the variables associated 
with HBV infection
AOR Adjusted odds ratio
* Statistically significant at P < 0.05
Variables, N = 508 AOR (95 % CI) P value
Sex
 Female 1
 Male 2.59 (1.179–5.688) 0.018*
Multiple sexual partners
 No 1
 Yes 4.171 (1.333–13.049) 0.014*
CD4 count
 <200 cells/μl 3.543 (1.119–11.214) 0.031*
 200–350 cells/μl 1.540 (0.462–5.136) 0.483
 351–499 cells/μl 2.226 (0.713–6.953) 0.168
 ≥500 cells/μl 1
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combination ART therapy; could be justified by the TDF, 
a nucleotide analogue, which efficiently inhibit the viral 
polymerase and replication cycle than the AZT. Regard-
ing sex distribution, males were frequently infected with 
HBV than females. Furthermore, in this study we were 
also observed a greater HBV prevalence among individu-
als having a history of multiple sexual partners. There-
fore, this highlights the need to strengthen and integrate 
HBV screening and treatment with the existing HIV/
AIDS Prevention and Control Policies.
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